Skip to main content
Top
Published in: Journal of Translational Medicine 1/2005

Open Access 01-12-2005 | Research

Influence of immunomagnetic enrichment on gene expression of tumor cells

Authors: Ute Woelfle, Elisabeth Breit, Klaus Pantel

Published in: Journal of Translational Medicine | Issue 1/2005

Login to get access

Abstract

Background

Metastasis is the leading cause of cancer-related death. Bone marrow (BM) is a frequent site for the settlement of disseminated tumor cells which occurs years before overt metastases signal incurability.

Methods

Here we describe a new method to assess the initial stage of metastasis development in cancer patients. By immunomagnetic selection with HER2/neu and EpCAM as catcher antigens single disseminated tumor cells can be enriched from BM samples. To examine whether the immunomagnetic enrichment technique may change gene expression in the selected tumor cells, we performed differential expression profiling with the breast cancer cell lines MCF-7 and BT474 as models. The profiles were performed using 1.2 Cancer Arrays (Clontech) containing 1176 cDNAs that can be grouped into different functional categories, such as signal transduction, cell cycle, adhesion, cytoskeleton plasticity, growth factors and others.

Results

The reproducibility of the gene expression profiling between duplicate cDNA-array experiments was assessed by two independent experiments with MCF-7 breast cancer cells. Scatter blot analysis revealed a good reproducibility of the cDNA array analysis (i.e. less than 10% difference in the gene expression between the arrays). Subsequent comparative cDNA-array analyses of immunobead-selected and unselected MCF-7 and BT474 cancer cells indicated that the antibody incubation during the immunomagnetic selection procedure did not considerably alter the gene expression profile.

Conclusion

The described method offers an excellent tool for the enrichment of micrometastatic tumor cells in BM without largely changing the gene expression pattern of these cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002, 2 (8): 563-72. 10.1038/nrc865.CrossRefPubMed Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002, 2 (8): 563-72. 10.1038/nrc865.CrossRefPubMed
2.
go back to reference Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003, 3 (6): 453-8. 10.1038/nrc1098.CrossRefPubMed Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003, 3 (6): 453-8. 10.1038/nrc1098.CrossRefPubMed
3.
go back to reference Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 2004, 4 (6): 448-56. 10.1038/nrc1370.CrossRefPubMed Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 2004, 4 (6): 448-56. 10.1038/nrc1370.CrossRefPubMed
4.
go back to reference Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G: Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992, 340 (8821): 685-9. 10.1016/0140-6736(92)92230-D.CrossRefPubMed Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G: Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet. 1992, 340 (8821): 685-9. 10.1016/0140-6736(92)92230-D.CrossRefPubMed
5.
go back to reference Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000, 342 (8): 525-33. 10.1056/NEJM200002243420801.CrossRefPubMed Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000, 342 (8): 525-33. 10.1056/NEJM200002243420801.CrossRefPubMed
6.
go back to reference Pantel K, Felber E, Schlimok G: Detection and characterization of residual disease in breast cancer. J Hematother. 1994, 3 (4): 315-22.CrossRefPubMed Pantel K, Felber E, Schlimok G: Detection and characterization of residual disease in breast cancer. J Hematother. 1994, 3 (4): 315-22.CrossRefPubMed
7.
go back to reference Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res. 2003, 9 (17): 6326-34.PubMed Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S: Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res. 2003, 9 (17): 6326-34.PubMed
8.
go back to reference Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H: Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 2000, 60 (24): 6868-74.PubMed Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H: Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 2000, 60 (24): 6868-74.PubMed
9.
go back to reference Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Muller V: Bi-specific Immunomagnetic enrichment of micrometastatic tumour cell clusters from Bone Marrow of Cancer Patients. Journal of Immunological Methods. 2004, Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Muller V: Bi-specific Immunomagnetic enrichment of micrometastatic tumour cell clusters from Bone Marrow of Cancer Patients. Journal of Immunological Methods. 2004,
10.
go back to reference Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996, 347 (9002): 649-53. 10.1016/S0140-6736(96)91203-9.CrossRefPubMed Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet. 1996, 347 (9002): 649-53. 10.1016/S0140-6736(96)91203-9.CrossRefPubMed
11.
go back to reference Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003, 63 (18): 5679-84.PubMed Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P: Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003, 63 (18): 5679-84.PubMed
12.
go back to reference Roh H, Pippin J, Boswell C, Drebin JA: Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res. 1998, 77 (1): 85-90. 10.1006/jsre.1998.5353.CrossRefPubMed Roh H, Pippin J, Boswell C, Drebin JA: Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res. 1998, 77 (1): 85-90. 10.1006/jsre.1998.5353.CrossRefPubMed
13.
go back to reference Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9: 1165-1172.PubMedCentralCrossRefPubMed Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989, 9: 1165-1172.PubMedCentralCrossRefPubMed
14.
go back to reference Mayfield S, Vaughn JP, Kute TE: DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat. 2001, 70 (2): 123-9. 10.1023/A:1012999012192.CrossRefPubMed Mayfield S, Vaughn JP, Kute TE: DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat. 2001, 70 (2): 123-9. 10.1023/A:1012999012192.CrossRefPubMed
15.
go back to reference Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A: KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol. 1998, 140 (6): 1519-34. 10.1083/jcb.140.6.1519.PubMedCentralCrossRefPubMed Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A: KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol. 1998, 140 (6): 1519-34. 10.1083/jcb.140.6.1519.PubMedCentralCrossRefPubMed
16.
go back to reference Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61 (12): 4892-900.PubMed Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001, 61 (12): 4892-900.PubMed
17.
go back to reference Klein CA, Blankenstein TJF, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002, 360: 683-689. 10.1016/S0140-6736(02)09838-0.CrossRefPubMed Klein CA, Blankenstein TJF, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002, 360: 683-689. 10.1016/S0140-6736(02)09838-0.CrossRefPubMed
18.
go back to reference Ree AH, Engebraaten O, Hovig E, Fodstad O: Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells. Int J Cancer. 2002, 97 (1): 28-33. 10.1002/ijc.1564.CrossRefPubMed Ree AH, Engebraaten O, Hovig E, Fodstad O: Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells. Int J Cancer. 2002, 97 (1): 28-33. 10.1002/ijc.1564.CrossRefPubMed
Metadata
Title
Influence of immunomagnetic enrichment on gene expression of tumor cells
Authors
Ute Woelfle
Elisabeth Breit
Klaus Pantel
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2005
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-3-12

Other articles of this Issue 1/2005

Journal of Translational Medicine 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.